FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110083669> ?p ?o ?g. }

• W2110083669 endingPage "1205" @default.
• W2110083669 startingPage "1195" @default.
• W2110083669 abstract "Antiretroviral drug combinations that include two nucleoside reverse transcriptase inhibitors and a protease inhibitor (PI) can suppress HIV replication to undetectable levels, improving the prognosis of HIV-infected individuals. The aim of therapy is complete virological suppression, with a current goal of <50 copies/mL HIV-1 RNA, in order to minimize the occurrence of drug resistance. Improved understanding of the pharmacology of PIs, primarily the importance of adequate drug exposure, has led to the widespread administration of PIs combined with a low 'boosting' dose of ritonavir. The combination of PIs with ritonavir can improve treatment responses in both treatment-naive and -experienced patients. Boosted PIs are an important therapeutic option for HIV and extensive data exist supporting their use. Use of individual agents should be guided by a resistance test at all stages of treatment from naive through to highly treatment-experienced patients. Currently, seven boosted PIs have both US and European licensing approval: indinavir, saquinavir, lopinavir, fosamprenavir, atazanavir, tipranavir and darunavir (formerly TMC114). The preferred first-line option in the USA is lopinavir. Many of the older PIs are less effective and/or have less favourable tolerability profiles. Emergent PI resistance is a major challenge in treatment, and it can be accelerated by partial suppression of viral load through inappropriate therapy combinations. Using the newer boosted PIs, which have more robust resistance profiles, with an optimized background regimen may increase the likelihood of complete viral suppression. This review discusses the relative strengths and weaknesses of boosted PIs in current practice." @default.
• W2110083669 created "2016-06-24" @default.
• W2110083669 creator A5047374087 @default.
• W2110083669 date "2007-10-03" @default.
• W2110083669 modified "2023-10-14" @default.
• W2110083669 title "Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients" @default.
• W2110083669 cites W1343435 @default.
• W2110083669 cites W15036525 @default.
• W2110083669 cites W1968485058 @default.
• W2110083669 cites W1980099829 @default.
• W2110083669 cites W1991665327 @default.
• W2110083669 cites W1999048558 @default.
• W2110083669 cites W2019952737 @default.
• W2110083669 cites W2026250203 @default.
• W2110083669 cites W2045131275 @default.
• W2110083669 cites W2048471427 @default.
• W2110083669 cites W2052991207 @default.
• W2110083669 cites W2060078516 @default.
• W2110083669 cites W2068946470 @default.
• W2110083669 cites W2078593189 @default.
• W2110083669 cites W2109350540 @default.
• W2110083669 cites W2117261241 @default.
• W2110083669 cites W2128877806 @default.
• W2110083669 cites W2133338060 @default.
• W2110083669 cites W2133955454 @default.
• W2110083669 cites W2139167304 @default.
• W2110083669 cites W2140708560 @default.
• W2110083669 cites W2144984387 @default.
• W2110083669 cites W2146935866 @default.
• W2110083669 cites W2148017922 @default.
• W2110083669 cites W2164349191 @default.
• W2110083669 cites W2312642584 @default.
• W2110083669 cites W2319472437 @default.
• W2110083669 cites W2410303438 @default.
• W2110083669 cites W2474833576 @default.
• W2110083669 cites W2977452327 @default.
• W2110083669 cites W2186178520 @default.
• W2110083669 doi "https://doi.org/10.1093/jac/dkm364" @default.
• W2110083669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17890281" @default.
• W2110083669 hasPublicationYear "2007" @default.
• W2110083669 type Work @default.
• W2110083669 sameAs 2110083669 @default.
• W2110083669 citedByCount "83" @default.
• W2110083669 countsByYear W21100836692012 @default.
• W2110083669 countsByYear W21100836692013 @default.
• W2110083669 countsByYear W21100836692014 @default.
• W2110083669 countsByYear W21100836692015 @default.
• W2110083669 countsByYear W21100836692017 @default.
• W2110083669 countsByYear W21100836692018 @default.
• W2110083669 countsByYear W21100836692019 @default.
• W2110083669 countsByYear W21100836692021 @default.
• W2110083669 countsByYear W21100836692022 @default.
• W2110083669 countsByYear W21100836692023 @default.
• W2110083669 crossrefType "journal-article" @default.
• W2110083669 hasAuthorship W2110083669A5047374087 @default.
• W2110083669 hasBestOaLocation W21100836692 @default.
• W2110083669 hasConcept C114851261 @default.
• W2110083669 hasConcept C126322002 @default.
• W2110083669 hasConcept C142462285 @default.
• W2110083669 hasConcept C143998085 @default.
• W2110083669 hasConcept C159047783 @default.
• W2110083669 hasConcept C197934379 @default.
• W2110083669 hasConcept C203014093 @default.
• W2110083669 hasConcept C2776937687 @default.
• W2110083669 hasConcept C2777182164 @default.
• W2110083669 hasConcept C2777210460 @default.
• W2110083669 hasConcept C2778375690 @default.
• W2110083669 hasConcept C2778414717 @default.
• W2110083669 hasConcept C2779182219 @default.
• W2110083669 hasConcept C2779298103 @default.
• W2110083669 hasConcept C2781143361 @default.
• W2110083669 hasConcept C2781413609 @default.
• W2110083669 hasConcept C2993143319 @default.
• W2110083669 hasConcept C3013748606 @default.
• W2110083669 hasConcept C71924100 @default.
• W2110083669 hasConcept C86803240 @default.
• W2110083669 hasConcept C89423630 @default.
• W2110083669 hasConcept C98274493 @default.
• W2110083669 hasConceptScore W2110083669C114851261 @default.
• W2110083669 hasConceptScore W2110083669C126322002 @default.
• W2110083669 hasConceptScore W2110083669C142462285 @default.
• W2110083669 hasConceptScore W2110083669C143998085 @default.
• W2110083669 hasConceptScore W2110083669C159047783 @default.
• W2110083669 hasConceptScore W2110083669C197934379 @default.
• W2110083669 hasConceptScore W2110083669C203014093 @default.
• W2110083669 hasConceptScore W2110083669C2776937687 @default.
• W2110083669 hasConceptScore W2110083669C2777182164 @default.
• W2110083669 hasConceptScore W2110083669C2777210460 @default.
• W2110083669 hasConceptScore W2110083669C2778375690 @default.
• W2110083669 hasConceptScore W2110083669C2778414717 @default.
• W2110083669 hasConceptScore W2110083669C2779182219 @default.
• W2110083669 hasConceptScore W2110083669C2779298103 @default.
• W2110083669 hasConceptScore W2110083669C2781143361 @default.
• W2110083669 hasConceptScore W2110083669C2781413609 @default.
• W2110083669 hasConceptScore W2110083669C2993143319 @default.
• W2110083669 hasConceptScore W2110083669C3013748606 @default.
• W2110083669 hasConceptScore W2110083669C71924100 @default.
• W2110083669 hasConceptScore W2110083669C86803240 @default.

• next